Research Index

The 2026 Demirtaş review in International Journal of Molecular Sciences (doi:10.3390/ijms27188344) grades BPC-157's rodent IRI evidence as mechanistically coherent but structurally deficient. Every included study is non-GLP, rodent-only, and originates from a narrow authorship cluster. The review identifies oxidative stress attenuation, NO-pathway modulation, and endothelial stabilisation as its mechanistic pillars — while flagging absent independent replication as the structural weakness.

As of 2026, no completed randomised controlled trial has evaluated BPC-157 in any tissue-healing indication in humans. Existing human data are limited to small, uncontrolled, unblinded gastrointestinal studies that fail regulatory acceptance standards. Adverse-event signals from real-world compounded use include immunogenicity risk from impurity-amplified aggregation, FAERS-captured hospitalisations, and an unquantified oncogenic concern tied to VEGFR2-mediated angiogenesis.

A 2026 critical review in International Journal of Molecular Sciences (Demirtaş, MDPI, doi:10.3390/ijms27188344) synthesises rodent ischemia–reperfusion injury (IRI) evidence for BPC-157 across skeletal muscle, liver, kidney, and lung. The peptide consistently attenuates oxidative stress markers, suppresses apoptotic signalling, and preserves microvascular integrity — but every study is non-GLP, rodent-only, and single-laboratory, placing the entire body of work at preclinical-evidence grade.

BPC-157's physicochemical profile — a 1,419 Da linear pentadecapeptide with unusual gastric acid stability and a sub-16-minute intravenous half-life in rats — simultaneously constrains and directs formulation strategy. Mateescu and colleagues' 2026 critical review in Pharmaceutics (doi:10.3390/pharmaceutics18050625) concludes oral delivery for gastrointestinal indications is the most defensible near-term route, while parenteral development is blocked by uncharacterised aggregation, impurity, and immunogenicity parameters.

Yes. Across both TRIUMPH-1 and TRIUMPH-2, retatrutide's triple GIP, GLP-1, and glucagon receptor agonism produced weight-loss and glycaemic outcomes exceeding published GLP-1 monotherapy benchmarks. The mechanistic advantage lies in the glucagon receptor's thermogenic and hepatic contributions. These are pathways that GLP-1R agonism alone cannot access at therapeutic doses.

A 2026 critical review in Pharmaceutics by Mateescu and colleagues (doi:10.3390/pharmaceutics18050625) identifies the absence of validated analytical methods for BPC-157 as a structural bottleneck that simultaneously blocks pharmacokinetic characterisation, pharmaceutical stability testing, impurity profiling, GMP batch release, and potency assay development. No other gap in BPC-157's development programme cascades across this many domains at once.

The 2026 Phase I trial of TT-P34 at CHDR Leiden enrolled 55 healthy volunteers and 12 early-stage Parkinson's disease patients, confirming safety and tolerability at all doses with no dose-limiting findings. Beyond those primary endpoints, the trial produced two signals relevant to disease modification: dose-dependent CSF exposure confirming blood-brain barrier penetration, and exploratory biomarker data indicating lysosomal pathway engagement.

The September 2026 first-patient-dosed Phase 1b/2a trial of KIT2014 — a cell-permeable inhaled peptide that disrupts the PI3Kγ–PKA–PDE3/4 macromolecular complex — represents the first clinical test of scaffold-targeted cAMP amplification in COPD. The 7-day, 36-patient, dose-ranging study in Australia positions FEV₁ kinetics and inflammatory biomarkers as early-efficacy readouts, with initial results expected Q1 2027.

A 2026 critical review in Pharmaceutics (Mateescu et al., doi:10.3390/pharmaceutics18050625) identifies indication selection as BPC-157's structural development bottleneck: preclinical activity across gastrointestinal, musculoskeletal, neurological, and cardiovascular models means no single indication can be chosen without mechanistic rationale that the receptor-orphan status cannot supply. Each indication demands a separate IND package, a distinct administration route, and a separate bioanalytical strategy.

Yes. A 2026 Molecular Therapy study (Jati et al., PMC12776420) demonstrated that exogenous catestatin (CST) supplementation reduced pathological tau species, lowered amyloid plaque burden, and attenuated gliosis in both PS19 tauopathy and 5xFAD amyloid mouse models. The operative mechanism involves CST-mediated suppression of adrenergic–epinephrine–PKA stress signaling, which converges on CDK5 and GSK-3β to reduce tau hyperphosphorylation and amyloidogenic APP processing.

AGM-380, a cell-penetrating peptide conjugate that binds the host phosphoprotein nucleolin (NCL), protected mice from lethal influenza A virus (IAV) challenge in a September 2026 PNAS Nexus study by markedly reducing pulmonary viral replication and lung pathology. When the trifluoroacetate variant AGM-380t was co-administered with oseltamivir, 100% of animals survived — a result no monotherapy achieved.

A 2026 scoping review by Kremen et al. (UCLA Health) screened 565 studies across six widely used unapproved peptides — BPC-157, TB-500, CJC-1295, MK-677, ipamorelin, and GHK-Cu — and found the overwhelming majority of evidence is preclinical. Human data are sparse, methodologically weak, and insufficient to establish efficacy for any of the six compounds in any indication.